PATIENT ENGAGEMENT

Patient Organization

The patient comes first

For Bayer, one of the world's leading specialty pharmaceutical companies, patients' health always comes first. Exchanging ideas and information with patient organizations on the basis of mutual trust is an important component of our work.

Such cooperation helps us to understand the needs of patients as they come to terms with their illness. This enables us to gear our research and development to these needs and to continue working on improved, new drugs and therapies.

Bayer cooperates with patient organizations in all kinds of therapeutic areas. We attach great importance to transparency in this context and protect the independence of our cooperation partners.

Our principles

Cooperation between Bayer and patient organizations is based on the following principles.

In order to provide patients with quality medical healthcare, a partnership with a patient organization pursues a specific objective concentrating on one or more of the following areas:
- raising awareness for certain diseases by improving diagnostic possibilities and preventive measures, knowing the patients' prospects and needs,
- understanding diseases and making sure that patients receive the best medical treatment available,
- improving the information provided to the patients,
- supporting medical innovations.
Bayer and the patient organizations comply with international and national laws and regulations.
Cooperation with a patient organization should neither influence decisions on a therapy nor promote or support specific therapies.
Bayer respects the neutrality and independence of patient organizations. Cooperation is based on a partnership between equals in which transparency and clarity are fundamental principles. This is why we also provide information on the extent and nature of support.

Overview of cooperation with patient organizations in Europe in 2022

The following is a list of patient organizations with which Bayer and its affiliated companies in Europe cooperated in 2022.

Headquarters:

Patient in Focus, Denmark

Bayer Company	Bayer AG
Contract date	03.09.2022
Amount	18.850 EUR
Purpose of interaction	Recruit a minimum of four patients and eight caregivers to help co-create and inform the development team of a "matching" feature to be implemented on the Bayer Vital patient portal.

Bayer Company	Bayer AG
Contract date	28.02.2022
Amount	675 EUR
Purpose of interaction	Bayer AG wishes to engage a Kidney Patient Council team member already recruited by Patient in Focus to participate in a Kidney Health Podcast on the topic of early chronic kidney disease and barriers to communication. The Kidney Health Podcast will take place within 6 weeks from this proposal.

International Diabetes Federation (IDF), Brussels, Belgium

Bayer Company	Bayer AG
Contract date	23.09.2022
Amount	30.000 EUR
Purpose of interaction	Co-operation Agreement: Strategic Corporate Partnership

Bayer Company	Bayer AG
Contract date	07.11.2022
Amount	63.000 EUR
Purpose of interaction	IDF Congress

Bayer Company	BCC AG
Contract date	2022
Amount	40.000 EUR
Purpose of interaction	Annual Sponsorship

AFCI Association française de la cystite interstitielle, France

Bayer Company	Bayer AG
Contract date	24.11.2022
Amount	900 EUR
Purpose of interaction	AdBoard Meeting "IC/BPS" - "Participation of Barbara Jankowski Patient perspective on interstitial cystitis/bladder pain syndrome"

Italian Interstitial Cystitis Association, Italy

Bayer Company	Bayer AG
Contract date	17.11.2022
Amount	600 EUR
Purpose of interaction	AdBoard Meeting "IC/BPS" - "Participation of Barbara Jankowski Patient perspective on interstitial cystitis/bladder pain syndrome"

European Kidney Patients´ Federation

Bayer Company	Bayer AG
Contract date	17.10.2022
Amount	20.000 EUR
Purpose of interaction	Provision of expert advice and co-creation of patient education materials. Provision of patient experience expertise in specific European countries. Organization of focus groups with patient representatives on topics of shared interest.

FEDERACIÓN ESPAÑOLA DE HEMOFILIA (FEDHEMO), Spain

Bayer Company	BCC AG
Contract date	21.10.2022
Amount	225 EUR
Purpose of interaction	European Patient Council (Hematology)

International Agency for the Prevention of Blindness (IAPB)

Bayer Company	BCC AG
Contract date	2022
Amount	94.760 EUR
Purpose of interaction	Annual Sponsorship

Bayer Company	BCC AG
Contract date	2022
Amount	20.000 GBP
Purpose of interaction	World Sight Day Sponsorship

Bayer Company	BCC AG
Contract date	2022
Amount	8.046,60 CHF
Purpose of interaction	Travel arrangements Singapore Joint Meeting 2022

Bayer Company	BCC AG
Contract date	2022
Amount	398,25 CHF
Purpose of interaction	Travel arrangements EURETINA 2022

Overview of the cooperation with patient organisations in Europe in 2021 to download as pdf.

Overview of the cooperation with patient organisations in Europe in 2020 to download as pdf.

Europe: